Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ekkehard Grünig (Heidelberg, Germany), Ekkehard Grünig, Benjamin Egenlauf, Tobias J. Lange, Ulrich Krüger, Rob Grover, Michelle Pernow, Andrew Traube, Thomas Viethen, Stephan Rosenkranz. Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH). Eur Respir J 2015; 46: Suppl. 59, 2114

Member's Comments

No comment yet.

Related content which might interest you: Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Pregnancy and pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 EPITOME-4, a phase 3b study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension following switch from Flolan® Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013